Figure 6
Figure 6. LPA abrogates TSP-1–mediated antiangiogenesis in vivo. Matrigel solutions containing FGF-2 (100 ng/mL) alone or in combination with TSP-1 (400 ng/mL) and/or LPA (5μM) were implanted subcutaneously into C57/BL6 mice. After 10 days, the plugs were removed, sectioned, and stained with Masson trichrome to measure neovascularization (A) or antibodies to CD36 (green) and CD31 (red) to assess relative expression levels (B). Vascular invasion was quantified from digital images using ImageJ Version 1.40g software. Representative images are shown in panel A top (scale bar = 50 μm). Bar graph shows mean ± SEM (NS, nonsignificant; *P < .01). Arrows in panel B indicate new blood vessels with weak CD36 expression.

LPA abrogates TSP-1–mediated antiangiogenesis in vivo. Matrigel solutions containing FGF-2 (100 ng/mL) alone or in combination with TSP-1 (400 ng/mL) and/or LPA (5μM) were implanted subcutaneously into C57/BL6 mice. After 10 days, the plugs were removed, sectioned, and stained with Masson trichrome to measure neovascularization (A) or antibodies to CD36 (green) and CD31 (red) to assess relative expression levels (B). Vascular invasion was quantified from digital images using ImageJ Version 1.40g software. Representative images are shown in panel A top (scale bar = 50 μm). Bar graph shows mean ± SEM (NS, nonsignificant; *P < .01). Arrows in panel B indicate new blood vessels with weak CD36 expression.

Close Modal

or Create an Account

Close Modal
Close Modal